TEST:

AssureMDx

Urine-based biomarkers have the potential to improve early BC detection and surveillance while reducing reliance on invasive procedures and costs related to the disease. Future efforts should prioritize cost-effective, large-scale multicentric studies to facilitate the adoption of these biomarkers into routine practice.

"VESICA HEALTH®...today announced that its flagship test, AssureMDx, has been formally recognized in the newly updated American Urological Association (AUA) Guidelines for the evaluation of patients with microscopic hematuria. Hematuria—blood in the urine—is the most common presenting symptom of bladder cancer."

"VESICA HEALTH, INC...announced the launch of its laboratory-developed AssureMDx™ test...AssureMDx represents a significant leap forward in bladder cancer diagnostics, offering unparalleled accuracy and reliability backed by rigorous scientific validation."